The global opioid use disorder treatment market is entering a strong growth phase, with the market projected to reach USD 4.07 billion in 2025 and expand to an estimated USD 9.4 billion by 2035, reflecting a CAGR of 11.5% during the forecast period. Market expansion is being driven by increasing opioid addiction rates, growing awareness of evidence-based treatment, government funding, and the wider adoption of medication-assisted treatments (MATs).

Demand for opioid use disorder treatment is increasing as healthcare systems seek more accessible and effective approaches to addiction management. Expanding telemedicine services, digital health platforms, personalized withdrawal management programs, and innovative pharmacological therapies are improving treatment availability while helping patients maintain continuity of care.

Request a Sample Report to Explore Key Market Insight:
https://marketmindsadvisory.com/request-sample/?report_id=26741 

Key Takeaways from Opioid Use Disorder Treatment Market

• The opioid use disorder treatment market is projected to reach USD 9.4 billion by 2035, expanding at a CAGR of 11.5%.
• Rising dependence on prescription opioids and illicit substances is increasing demand for treatment services.
• Buprenorphine remains the leading drug type, accounting for 82.4% of the market in 2025.
• Oral administration represents the largest route, with a 63.7% market share in 2025.
• Hospital pharmacies lead distribution channels with a 40.2% market share.
• North America dominates the market with a 50.2% share, supported by strong healthcare infrastructure and government initiatives.
• Asia-Pacific is expected to record the fastest regional growth, with a 10.5% CAGR through 2035.

Opioid Use Disorder Treatment Market Trends

AI-powered addiction recovery is enabling personalized treatment

Artificial intelligence is emerging as an important technology in opioid use disorder management. AI-enabled platforms can support personalized treatment recommendations by analyzing patient information, treatment adherence, behavioral patterns, and recovery progress. These capabilities can help providers identify changing patient needs and tailor interventions more efficiently.

The integration of digital technologies with conventional addiction treatment is also improving patient engagement. AI-supported recovery programs can complement clinical services by providing continuous digital assistance and helping treatment providers monitor progress between appointments.

Long-acting therapies are improving treatment adherence

The adoption of buprenorphine patches, long-acting injectables, and other extended-duration treatment options is creating new opportunities within the opioid use disorder treatment market. These therapies can reduce the frequency of medication administration and support treatment continuity.

Growing interest in long-acting formulations reflects the industry's focus on improving patient compliance while reducing treatment interruptions. Pharmaceutical companies are therefore investing in therapies designed to provide sustained therapeutic effects and more convenient treatment experiences.

Drivers, Opportunities & Restraints

Rising opioid addiction rates are driving treatment demand

Growing dependency on prescription opioids and illicit substances continues to create substantial demand for effective treatment solutions. Increasing public awareness of opioid use disorder is also encouraging more individuals to seek professional assistance and evidence-based recovery programs.

Government funding and policy support are expanding accessibility

Government initiatives, Medicaid coverage expansion, federal grants, and rehabilitation programs are supporting broader access to opioid addiction treatment. Increased public-sector investment is helping healthcare organizations develop treatment infrastructure while encouraging innovation across the pharmaceutical and digital health sectors.

Neurostimulation therapies are creating new opportunities

Advancements in non-invasive neurostimulation are creating opportunities for alternative or complementary approaches to conventional medication-assisted treatment. These technologies are attracting attention as healthcare providers and researchers explore additional methods for managing withdrawal symptoms and supporting recovery.

Opioid Use Disorder Treatment Market Segmentation

By Drug Type

• Buprenorphine: 82.4% market share in 2025
• Methadone: 10.6%
• Naltrexone: 7.0%

By Route of Administration

• Oral: 63.7%
• Parenteral (Injectable): 36.3%

By Distribution Channel

• Hospital Pharmacies: 40.2%
• Retail Pharmacies: 34.6%
• Online Pharmacies: 25.2%

Opioid Use Disorder Treatment Market Regional Analysis

North America leads the opioid use disorder treatment market, accounting for 50.2% of the market in 2025. The region benefits from high treatment demand, substantial government initiatives, established healthcare infrastructure, and increasing investment in addiction recovery services. North America is expected to expand at a CAGR of 9.7% through 2035.

Europe represents another significant market, holding a 24.8% share in 2025 and projected to grow at an 8.9% CAGR. Increasing regulatory approvals, rehabilitation investments, and greater awareness of opioid dependency are supporting market development across the region.

Asia-Pacific is expected to be the fastest-growing regional market, with a projected 10.5% CAGR from 2025 to 2035. Expanding healthcare access, policy reforms, opioid crisis management initiatives, and growing investment in addiction treatment are creating attractive opportunities for market participants.

Competitive Landscape

The competitive landscape of the opioid use disorder treatment market is characterized by pharmaceutical companies, biotechnology firms, and healthcare technology providers developing innovative therapies and treatment platforms. Companies are increasingly focusing on long-acting opioid antagonists, next-generation treatment approaches, digital rehabilitation solutions, and AI-powered patient management technologies.

Strategic partnerships with telehealth providers are also becoming an important competitive strategy as companies seek to expand treatment accessibility and strengthen patient engagement. Accelerated regulatory pathways and investments in innovative formulations are expected to further shape competition through 2035.

Leading Market Players

Key companies operating in the opioid use disorder treatment market include:

• Trevena, Inc.
• Opiate Pharmaceutical
• Aphios Corporation
• Kyowa Kirin Co., Ltd.
• Gamida Cell
• Novartis AG
• Titan Pharmaceuticals, Inc.
• Hikma Pharmaceuticals
• MediciNova, Inc.
• Alkermes, Inc.
• BioDelivery Sciences International, Inc.

Browse the Complete Research Report:

Related Reports:

Antimicrobial Coated Medical Devices Market: https://marketmindsadvisory.com/antimicrobial-coated-medical-devices-market/ 

Anti Osteoporosis Therapy and Fracture Healing Market: https://marketmindsadvisory.com/anti-osteoporosis-therapy-and-fracture-healing-market/ 

Neurology Services Market: https://marketmindsadvisory.com/neurology-services-market/ 

Why choose Market Minds Advisory

Market Minds Advisory delivers decision-grade intelligence trusted by executives across machinery & equipment, packaging, chemical, automotive, information & communication technology, food & beverage, consumer goods, healthcare and other industries. We provide market expansion strategies, go-to-market strategies, market share acceleration, brand positioning analysis, and account enablement and growth. Our forecasting methodology integrates primary interviews, proprietary demand models and continuous market validation to ensure accuracy in volatile and emerging industries. With over 10 years of industry experience and insights derived from primary interviews with several industry stakeholders, our research provides actionable insights and white space analysis for the emerging segments providing the opportunity gaps in the market accounting recent market developments and geopolitical risks. We believe in unlocking growth by helping businesses to see the future of their markets.

Contact Us

Market Minds Advisory

86 Great Portland Street, Mayfair, London,

W1W 7FG, England, United Kingdom

T: +44 020 3807 7725

Email:sales@marketmindsadvisory.com

Website:https://marketmindsadvisory.com/

LinkedIn: https://www.linkedin.com/company/market-minds-advisory/

Facebook: https://www.facebook.com/resvaultmmadvisory/

Twitter: https://x.com/MarketMindsA

Instagram: https://www.instagram.com/marketmindsadvisory